---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020229"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T19:35:28.252663+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix reports record Q1 revenue of $921K; operating loss $568K

## Summary
- Q1 2024 revenue $921K, largest Q1 ever; operating loss $568K.
- Cash $2.7M, inventory $2.6M; balance sheet strong.
- GSA contract for VA sales effective May 1, 2024, expected to accelerate adoption.
- UroShield RCT study at University of Michigan begins pilot phase (up to 30 patients).
- PainShield adoption growing in VA and workers' comp markets.

## SEC filing metadata
- accession: 0001493152-24-020229
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315224020229/0001493152-24-020229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315224020229/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020229
- JSON: https://secwatch.observer/filing/0001493152-24-020229.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020229.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.